Technical Analysis for HURA - TuHURA Biosciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 3.95% | |
Inside Day | Range Contraction | 3.95% | |
Wide Bands | Range Expansion | 3.95% | |
Below Lower BB | Weakness | 3.95% | |
Lower Bollinger Band Touch | Weakness | 3.95% | |
Oversold Stochastic | Weakness | 3.95% | |
Wide Bands | Range Expansion | 13.25% | |
Below Lower BB | Weakness | 13.25% | |
Down 3 Days in a Row | Weakness | 13.25% | |
Down 4 Days in a Row | Weakness | 13.25% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 3 hours ago |
Down 5% | about 3 hours ago |
Down 3% | about 3 hours ago |
Down 2 % | about 3 hours ago |
Down 1% | about 3 hours ago |
Get a Trading Sidekick!
- Earnings date: 10/09/2024
TuHURA Biosciences, Inc. Description
TuHURA Biosciences is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced Merkel Cell Carcinoma. In addition, TuHURA is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Immune System Immunotherapy Tumor Cancer Immunotherapy Antineoplastic Drugs Checkpoint Inhibitor Tumor Microenvironment Pembrolizumab Adjunctive Therapy
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 17.3635 |
52 Week Low | 2.835 |
Average Volume | 111,894 |
200-Day Moving Average | 6.02 |
50-Day Moving Average | 5.80 |
20-Day Moving Average | 4.88 |
10-Day Moving Average | 4.45 |
Average True Range | 0.66 |
RSI (14) | 26.47 |
ADX | 42.45 |
+DI | 7.99 |
-DI | 38.57 |
Chandelier Exit (Long, 3 ATRs) | 4.22 |
Chandelier Exit (Short, 3 ATRs) | 4.90 |
Upper Bollinger Bands | 6.46 |
Lower Bollinger Band | 3.29 |
Percent B (%b) | 0.0 |
BandWidth | 64.97 |
MACD Line | -0.64 |
MACD Signal Line | -0.46 |
MACD Histogram | -0.1852 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.91 | ||||
Resistance 3 (R3) | 3.86 | 3.61 | 3.80 | ||
Resistance 2 (R2) | 3.61 | 3.45 | 3.63 | 3.77 | |
Resistance 1 (R1) | 3.45 | 3.36 | 3.53 | 3.50 | 3.73 |
Pivot Point | 3.20 | 3.20 | 3.24 | 3.22 | 3.20 |
Support 1 (S1) | 3.04 | 3.04 | 3.12 | 3.09 | 2.85 |
Support 2 (S2) | 2.79 | 2.95 | 2.81 | 2.81 | |
Support 3 (S3) | 2.63 | 2.79 | 2.78 | ||
Support 4 (S4) | 2.68 |